PDGFRA and gastrointestinal stromal tumor: These data emphasize that mutational status must play a predominant role in the clinical management of patients and that new findings are necessary to establish the mechanisms responsible for imatinib resistance in specific subsets of tumors like PDGFRA D842V mutant and WT GIST.